CA2190275A1 - Triage pour la detection de modulateurs des cytokines - Google Patents

Triage pour la detection de modulateurs des cytokines

Info

Publication number
CA2190275A1
CA2190275A1 CA002190275A CA2190275A CA2190275A1 CA 2190275 A1 CA2190275 A1 CA 2190275A1 CA 002190275 A CA002190275 A CA 002190275A CA 2190275 A CA2190275 A CA 2190275A CA 2190275 A1 CA2190275 A1 CA 2190275A1
Authority
CA
Canada
Prior art keywords
promoter
protein
rel
receptor
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002190275A
Other languages
English (en)
Inventor
Thomas Hermann
John W. Pike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2190275A1 publication Critical patent/CA2190275A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet un procédé de triage pour détecter des agents de traitement de maladies et d'états pathologiques affectés par les cytokines. Ces agents interagissent directement ou indirectement avec un récepteur intracellulaire, qui, à son tour, module la liaison d'une protéine de type rel, d'un complexe de protéines de type rel, ou d'autres protéines de transcription sur un site rel sur le promoteur d'un gène de cytokine. Le récepteur intracellulaire peut être le récepteur d'oestrogène, les récepteurs d'acide rétinoïde, les récepteurs de rétinoïde X, le récepteur de glucocorticoïde, les récepteurs de progestérone, le récepteur d'androgène, les récepteurs d'hormone thyroïdienne, ou le récepteur de vitamine D. Les agents de sélection peuvent être utilisés pour traiter l'ostéoporose, la polyarthrite rhumatoïde, l'inflammation, le psoriasis, le sarcome de Kaposi, le choc septique et les myélomes multiples.
CA002190275A 1994-05-18 1995-05-15 Triage pour la detection de modulateurs des cytokines Abandoned CA2190275A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24547094A 1994-05-18 1994-05-18
US08/245,470 1994-05-18

Publications (1)

Publication Number Publication Date
CA2190275A1 true CA2190275A1 (fr) 1995-11-23

Family

ID=22926786

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002190275A Abandoned CA2190275A1 (fr) 1994-05-18 1995-05-15 Triage pour la detection de modulateurs des cytokines

Country Status (5)

Country Link
EP (1) EP0765475A1 (fr)
JP (1) JPH10500485A (fr)
AU (1) AU2646295A (fr)
CA (1) CA2190275A1 (fr)
WO (1) WO1995031722A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4436352A1 (de) * 1994-10-12 1996-04-18 Kay Brune Verfahren zur diagnostischen Beurteilung und Verlaufskontrolle sowie Arzneimittel zur Therapie von Schockzuständen beim Menschen
GB9424497D0 (en) * 1994-12-05 1995-01-25 Karobio Ab Reporter cell line
GB9608133D0 (en) * 1996-04-19 1996-06-26 Gemini International Holdings Diagnostic method and apparatus
US6692928B1 (en) 1996-07-19 2004-02-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular agents
US5728534A (en) 1996-07-19 1998-03-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular therapeutic agents
DE69635462T2 (de) * 1996-09-27 2006-08-17 The Board of Regents, The University of Texas System, Austin Screeningmethoden für glucocorticoidrezeptor-bindende substanzen unter verwendung von trypterygium wilfordii zubereitungen
EP0987552A3 (fr) * 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée
CN1341213A (zh) * 1999-02-18 2002-03-20 中外制药株式会社 筛选具有维生素d受体亲和性的化合物的方法
US6764826B2 (en) 2000-06-08 2004-07-20 Board Of Regents, The University Of Texas System Inhibitors of C-reactive protein induced inflammation
HRP20040102A2 (en) * 2001-07-09 2004-10-31 Combinatorx Combinations for the treatment of inflammatory disorders
AU2003219136A1 (en) * 2002-02-25 2003-09-09 Akzo Nobel N.V. Estrogen receptor interaction with a transcription factor
WO2005030994A1 (fr) 2003-09-26 2005-04-07 International Institute Of Molecular And Cell Biology In Warsaw Cellules et procedes utilises dans la caracterisation de l'activite immunotoxique de substances xenobiotiques
US8519158B2 (en) 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
EP2511382A1 (fr) * 2011-04-14 2012-10-17 Université de Strasbourg Procédé pour identifier de nouvelles molécules anti-inflammatoires avec une transrepression directe réduite de gènes induite par glucocorticoïdes
WO2020214834A1 (fr) 2019-04-19 2020-10-22 Ligand Pharmaceuticals Inc. Formes cristallines et procédés de production de formes cristallines d'un composé

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007072A1 (fr) * 1990-10-10 1992-04-30 La Jolla Cancer Research Foundation Procede d'inhibition de transcription utilisant des recepteurs nucleaires

Also Published As

Publication number Publication date
WO1995031722A1 (fr) 1995-11-23
EP0765475A1 (fr) 1997-04-02
AU2646295A (en) 1995-12-05
JPH10500485A (ja) 1998-01-13

Similar Documents

Publication Publication Date Title
Gametchua et al. Plasma membrane-resident glucocorticoid receptors in rodent lymphoma and human leukemia models
Ram et al. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone
Takahashi et al. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASxα to the receptor
Froesch et al. BAG-1L protein enhances androgen receptor function
Sánchez-Elsner et al. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression
Ramalingam et al. Glucocorticoid inhibition of fibroblast proliferation and regulation of the cyclin kinase inhibitor p21Cip1
Hecht et al. Evidence that the β-isoform of the human glucocorticoid receptor does not act as a physiologically significant repressor
Roberts et al. Degradation of the basic helix-loop-helix/Per-ARNT-Sim homology domain dioxin receptor via the ubiquitin/proteasome pathway
CA2190275A1 (fr) Triage pour la detection de modulateurs des cytokines
Hou et al. The functional role of an interleukin 6-inducible CDK9· STAT3 complex in human γ-fibrinogen gene expression
Pouliot et al. Role of Smad1 and Smad4 proteins in the induction of p21 WAF1, Clp1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells
Curtis et al. Uterine estrogen receptor interaction with estrogen-responsive DNA sequences in vitro: effects of ligand binding on receptor-DNA complexes
JP3131649B2 (ja) オーファン レセプター
Sherman et al. Role of signal transducers and activators of transcription 1 and-3 in inducible regulation of the human angiotensinogen gene by interleukin-6
Milad et al. Interaction of the progesterone receptor with binding proteins for FK506 and cyclosporin A.
Lantinga-van Leeuwen et al. Cloning and cellular localization of the canine progesterone receptor: co-localization with growth hormone in the mammary gland
Driscoll et al. Footprint analysis of estrogen receptor binding to adjacent estrogen response elements
WO1997009418A1 (fr) Corepresseur de transcription interagissant avec les recepteurs nucleaires des hormones, et ses utilisations
Burkart et al. Mechanism of repression of the inhibin α-subunit gene by inducible 3′, 5′-cyclic adenosine monophosphate early repressor
Ulukus et al. Expression of interleukin-8 receptors in patients with adenomyosis
JP4071033B2 (ja) 物質のホルモン作用の試験方法
Faitar et al. EVI5 is a novel centrosomal protein that binds to α-and γ-tubulin
Chauchereau et al. Phosphorylation of transfected wild type and mutated progesterone receptors.
Clemm et al. Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor
Li et al. Identification of glucocorticoid receptor domains involved in transrepression of transforming growth factor-β action

Legal Events

Date Code Title Description
FZDE Dead